Clinical and economic assessment: infliximab for the treatment of Crohn's disease
Marshall J K, Blackhouse G, Goeree R, Brazier N, Irvine E J, O'Brien BJ
Record ID 32002000371
English, French
Authors' objectives:
(1) To review available data supporting the efficacy, effectiveness and adverse effects of infliximab in the treatment of patients with Crohn's disease (CD).
(2) To conduct a primary cost-utility analysis of infliximab treatment for patients with active CD resistant to conventional therapy.
Authors' recommendations:
Infliximab appears to be clinically effective for the treatment of fistulizing CD and active CD resistant to conventional therapy. While more information on the long-term consequences of infliximab therapy is needed, its short-term safety profile is acceptable. A cost-utility analysis of infliximab in treatment-resistant active CD suggests the incremental costs per additional quality-adjusted life year exceed traditional benchmarks for cost per QALY.
Authors' methods:
Systematic review, Economic evaluation
Details
Project Status:
Completed
URL for project:
https://www.ccohta.ca/
Year Published:
2002
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Costs and Cost Analysis
- Crohn Disease
Contact
Organisation Name:
Canadian Coordinating Office for Health Technology Assessment
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553, Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Coordinating Office for Health Technology Assessment (CCOHTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.